IBDEI0C0 ; ; 13-FEB-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 13, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16026,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16026,1,4,0)
 ;;=4^454.1
 ;;^UTILITY(U,$J,358.3,16026,1,5,0)
 ;;=5^Dermatitis,Stasis
 ;;^UTILITY(U,$J,358.3,16026,2)
 ;;=^125435
 ;;^UTILITY(U,$J,358.3,16027,0)
 ;;=424.90^^107^951^31
 ;;^UTILITY(U,$J,358.3,16027,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16027,1,4,0)
 ;;=4^424.90
 ;;^UTILITY(U,$J,358.3,16027,1,5,0)
 ;;=5^Endocarditis
 ;;^UTILITY(U,$J,358.3,16027,2)
 ;;=^40327
 ;;^UTILITY(U,$J,358.3,16028,0)
 ;;=456.1^^107^951^32
 ;;^UTILITY(U,$J,358.3,16028,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16028,1,4,0)
 ;;=4^456.1
 ;;^UTILITY(U,$J,358.3,16028,1,5,0)
 ;;=5^Esoph Varices w/o Bleed
 ;;^UTILITY(U,$J,358.3,16028,2)
 ;;=^269836
 ;;^UTILITY(U,$J,358.3,16029,0)
 ;;=403.10^^107^951^37
 ;;^UTILITY(U,$J,358.3,16029,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16029,1,4,0)
 ;;=4^403.10
 ;;^UTILITY(U,$J,358.3,16029,1,5,0)
 ;;=5^HTN w/ Renal Failure I-IV or Unspec
 ;;^UTILITY(U,$J,358.3,16029,2)
 ;;=^334271
 ;;^UTILITY(U,$J,358.3,16030,0)
 ;;=457.1^^107^951^61
 ;;^UTILITY(U,$J,358.3,16030,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16030,1,4,0)
 ;;=4^457.1
 ;;^UTILITY(U,$J,358.3,16030,1,5,0)
 ;;=5^Lymphedema,Acquired
 ;;^UTILITY(U,$J,358.3,16030,2)
 ;;=^87693
 ;;^UTILITY(U,$J,358.3,16031,0)
 ;;=436.^^107^951^74
 ;;^UTILITY(U,$J,358.3,16031,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16031,1,4,0)
 ;;=4^436.
 ;;^UTILITY(U,$J,358.3,16031,1,5,0)
 ;;=5^Stroke,Acute Ill Defined
 ;;^UTILITY(U,$J,358.3,16031,2)
 ;;=^2710
 ;;^UTILITY(U,$J,358.3,16032,0)
 ;;=451.9^^107^951^75
 ;;^UTILITY(U,$J,358.3,16032,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16032,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,16032,1,5,0)
 ;;=5^Thrombophlebitis
 ;;^UTILITY(U,$J,358.3,16032,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,16033,0)
 ;;=446.6^^107^951^76
 ;;^UTILITY(U,$J,358.3,16033,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16033,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,16033,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpu
 ;;^UTILITY(U,$J,358.3,16033,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,16034,0)
 ;;=435.9^^107^951^77
 ;;^UTILITY(U,$J,358.3,16034,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16034,1,4,0)
 ;;=4^435.9
 ;;^UTILITY(U,$J,358.3,16034,1,5,0)
 ;;=5^Transient Ischemic Attack
 ;;^UTILITY(U,$J,358.3,16034,2)
 ;;=^21635
 ;;^UTILITY(U,$J,358.3,16035,0)
 ;;=455.6^^107^951^58
 ;;^UTILITY(U,$J,358.3,16035,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16035,1,4,0)
 ;;=4^455.6
 ;;^UTILITY(U,$J,358.3,16035,1,5,0)
 ;;=5^Hemorrhoids
 ;;^UTILITY(U,$J,358.3,16035,2)
 ;;=^123922
 ;;^UTILITY(U,$J,358.3,16036,0)
 ;;=403.90^^107^951^34
 ;;^UTILITY(U,$J,358.3,16036,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16036,1,4,0)
 ;;=4^403.90
 ;;^UTILITY(U,$J,358.3,16036,1,5,0)
 ;;=5^HTN w/ CKD I-IV,Unspec
 ;;^UTILITY(U,$J,358.3,16036,2)
 ;;=^334272
 ;;^UTILITY(U,$J,358.3,16037,0)
 ;;=271.3^^107^952^10
 ;;^UTILITY(U,$J,358.3,16037,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16037,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,16037,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,16037,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,16038,0)
 ;;=251.2^^107^952^28
 ;;^UTILITY(U,$J,358.3,16038,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16038,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,16038,1,5,0)
 ;;=5^Hypoglycemia Nos
 ;;^UTILITY(U,$J,358.3,16038,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,16039,0)
 ;;=257.2^^107^952^29
 ;;^UTILITY(U,$J,358.3,16039,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16039,1,4,0)
 ;;=4^257.2
 ;;^UTILITY(U,$J,358.3,16039,1,5,0)
 ;;=5^Hypogonadism,Male
 ;;^UTILITY(U,$J,358.3,16039,2)
 ;;=^88213
 ;;^UTILITY(U,$J,358.3,16040,0)
 ;;=253.2^^107^952^32
 ;;^UTILITY(U,$J,358.3,16040,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16040,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,16040,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,16040,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,16041,0)
 ;;=278.00^^107^952^39
 ;;^UTILITY(U,$J,358.3,16041,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16041,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,16041,1,5,0)
 ;;=5^Obesity (2nd dx only)
 ;;^UTILITY(U,$J,358.3,16041,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,16042,0)
 ;;=278.01^^107^952^38
 ;;^UTILITY(U,$J,358.3,16042,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16042,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,16042,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,16042,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,16043,0)
 ;;=250.80^^107^952^9
 ;;^UTILITY(U,$J,358.3,16043,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16043,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,16043,1,5,0)
 ;;=5^DM Type II with LE Ulcer
 ;;^UTILITY(U,$J,358.3,16043,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,16044,0)
 ;;=250.00^^107^952^4
 ;;^UTILITY(U,$J,358.3,16044,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16044,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,16044,1,5,0)
 ;;=5^DM Type II Dm W/O Complications
 ;;^UTILITY(U,$J,358.3,16044,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,16045,0)
 ;;=250.40^^107^952^5
 ;;^UTILITY(U,$J,358.3,16045,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16045,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,16045,1,5,0)
 ;;=5^DM Type II Dm with Nephropathy
 ;;^UTILITY(U,$J,358.3,16045,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,16046,0)
 ;;=250.50^^107^952^8
 ;;^UTILITY(U,$J,358.3,16046,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16046,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,16046,1,5,0)
 ;;=5^DM Type II w/ Ophthal Manifest
 ;;^UTILITY(U,$J,358.3,16046,2)
 ;;=DM Type II w/ Ophthal Manifest^267839^362.02
 ;;^UTILITY(U,$J,358.3,16047,0)
 ;;=250.60^^107^952^6
 ;;^UTILITY(U,$J,358.3,16047,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16047,1,4,0)
 ;;=4^250.60
 ;;^UTILITY(U,$J,358.3,16047,1,5,0)
 ;;=5^DM Type II Dm with Neuropathy
 ;;^UTILITY(U,$J,358.3,16047,2)
 ;;=^267841^357.2
 ;;^UTILITY(U,$J,358.3,16048,0)
 ;;=250.70^^107^952^7
 ;;^UTILITY(U,$J,358.3,16048,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16048,1,4,0)
 ;;=4^250.70
 ;;^UTILITY(U,$J,358.3,16048,1,5,0)
 ;;=5^DM Type II Dm with Peripheral Vasc Dis
 ;;^UTILITY(U,$J,358.3,16048,2)
 ;;=^267843^443.81
 ;;^UTILITY(U,$J,358.3,16049,0)
 ;;=250.01^^107^952^3
 ;;^UTILITY(U,$J,358.3,16049,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16049,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,16049,1,5,0)
 ;;=5^DM Type I DM W/O Complications
 ;;^UTILITY(U,$J,358.3,16049,2)
 ;;=^33586
 ;;^UTILITY(U,$J,358.3,16050,0)
 ;;=272.0^^107^952^20
 ;;^UTILITY(U,$J,358.3,16050,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16050,1,4,0)
 ;;=4^272.0
 ;;^UTILITY(U,$J,358.3,16050,1,5,0)
 ;;=5^Hypercholesterolemia, Pure
 ;;^UTILITY(U,$J,358.3,16050,2)
 ;;=Hypercholesterolemia, Pure^59973
 ;;^UTILITY(U,$J,358.3,16051,0)
 ;;=272.1^^107^952^26
 ;;^UTILITY(U,$J,358.3,16051,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16051,1,4,0)
 ;;=4^272.1
 ;;^UTILITY(U,$J,358.3,16051,1,5,0)
 ;;=5^Hypertriglyceridemia, Pure
 ;;^UTILITY(U,$J,358.3,16051,2)
 ;;=Hypertriglyceridemia, Pure^101303
 ;;^UTILITY(U,$J,358.3,16052,0)
 ;;=272.2^^107^952^23
 ;;^UTILITY(U,$J,358.3,16052,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16052,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,16052,1,5,0)
 ;;=5^Hyperlipidemia, Mixed
 ;;^UTILITY(U,$J,358.3,16052,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,16053,0)
 ;;=275.42^^107^952^19
 ;;^UTILITY(U,$J,358.3,16053,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16053,1,4,0)
 ;;=4^275.42
 ;;^UTILITY(U,$J,358.3,16053,1,5,0)
 ;;=5^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,16053,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,16054,0)
 ;;=275.41^^107^952^27
 ;;^UTILITY(U,$J,358.3,16054,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16054,1,4,0)
 ;;=4^275.41
 ;;^UTILITY(U,$J,358.3,16054,1,5,0)
 ;;=5^Hypocalcaemia
 ;;^UTILITY(U,$J,358.3,16054,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,16055,0)
 ;;=276.7^^107^952^21
 ;;^UTILITY(U,$J,358.3,16055,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16055,1,4,0)
 ;;=4^276.7
 ;;^UTILITY(U,$J,358.3,16055,1,5,0)
 ;;=5^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,16055,2)
 ;;=^60042
 ;;^UTILITY(U,$J,358.3,16056,0)
 ;;=275.2^^107^952^17
 ;;^UTILITY(U,$J,358.3,16056,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16056,1,4,0)
 ;;=4^275.2
 ;;^UTILITY(U,$J,358.3,16056,1,5,0)
 ;;=5^Hyper Or Hypomagnesemia
 ;;^UTILITY(U,$J,358.3,16056,2)
 ;;=^35626
 ;;^UTILITY(U,$J,358.3,16057,0)
 ;;=276.0^^107^952^24
 ;;^UTILITY(U,$J,358.3,16057,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16057,1,4,0)
 ;;=4^276.0
 ;;^UTILITY(U,$J,358.3,16057,1,5,0)
 ;;=5^Hypernatremia
 ;;^UTILITY(U,$J,358.3,16057,2)
 ;;=^60144
 ;;^UTILITY(U,$J,358.3,16058,0)
 ;;=276.1^^107^952^30
 ;;^UTILITY(U,$J,358.3,16058,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16058,1,4,0)
 ;;=4^276.1
 ;;^UTILITY(U,$J,358.3,16058,1,5,0)
 ;;=5^Hyponatremia
 ;;^UTILITY(U,$J,358.3,16058,2)
 ;;=Hyponatremia^60722
 ;;^UTILITY(U,$J,358.3,16059,0)
 ;;=275.3^^107^952^18
 ;;^UTILITY(U,$J,358.3,16059,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16059,1,4,0)
 ;;=4^275.3
 ;;^UTILITY(U,$J,358.3,16059,1,5,0)
 ;;=5^Hyper Or Hypophosphatemia
 ;;^UTILITY(U,$J,358.3,16059,2)
 ;;=^93796
 ;;^UTILITY(U,$J,358.3,16060,0)
 ;;=240.0^^107^952^13
 ;;^UTILITY(U,$J,358.3,16060,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16060,1,4,0)
 ;;=4^240.0
 ;;^UTILITY(U,$J,358.3,16060,1,5,0)
 ;;=5^Goiter, Simple
 ;;^UTILITY(U,$J,358.3,16060,2)
 ;;=^259806
 ;;^UTILITY(U,$J,358.3,16061,0)
 ;;=241.1^^107^952^12
 ;;^UTILITY(U,$J,358.3,16061,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16061,1,4,0)
 ;;=4^241.1
 ;;^UTILITY(U,$J,358.3,16061,1,5,0)
 ;;=5^Goiter, Nontox, Multinod
 ;;^UTILITY(U,$J,358.3,16061,2)
 ;;=^267790
 ;;^UTILITY(U,$J,358.3,16062,0)
 ;;=241.0^^107^952^42
 ;;^UTILITY(U,$J,358.3,16062,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16062,1,4,0)
 ;;=4^241.0
 ;;^UTILITY(U,$J,358.3,16062,1,5,0)
 ;;=5^Thyroid Nodule, Nontoxic
 ;;^UTILITY(U,$J,358.3,16062,2)
 ;;=^83865
